Posted by Michael Wonder on 25 Mar 2024
FDA grants Argenica rare paediatric disease designation for ARG-007 in the treatment of HIE
25 March 2024 - Argenica Therapeutics is pleased to announce the US FDA has granted its neuroprotective drug ARG-007 rare paediatric disease designation for the treatment of hypoxic ischaemic encephalopathy in newborn term infants.
Argenica is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes.
